Scotland has become the first part of the UK to approve two new cancer drugs for routine use in the NHS
Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy
Analysis of Phase 2 data evaluating induced memory T cell immunity following treatment with AGS-003 in combination with sunitinib presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
On Thursday, November 21, participants will climb stairs at TCF Bank Stadium at the University of Minnesota. You can choose your level of participation on the day of the event; you can skip the climb and go straight to the reception, or you can choose one of several climbing tiers. The climb begins at 5:30pm with the reception following.
In a study of 256 patients treated surgically for renal cell carcinoma (RCC) with venous thrombus at the University of Texas MD Anderson Cancer Center between 1993 and 2009, median recurrence-free interval was significantly shorter in patients with positive vascular margins (22.1 months vs 70.2 months). However, although tumour invasion into the vein wall at the resection margin was independently predictive of local recurrence, multivariable analysis revealed that it had minimal effect on systemic recurrence or cancer-specific survival.
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway.
A panel of experts differs in opinion on the treatment of various kidney cancers. Recorded at M. D. Anderson Cancer Center, Houston, Texas, in 2013.
Standard treatment of renal neoplasms remains surgical resection, and nephrectomy for localised renal cell carcinoma (RCC) still has the best chance of cure with excellent long-term results. For smaller renal masses, especially stage T1a tumours less than 4 cm, nephron-sparing surgery is often employed. However, small incidentally detected renal masses pose an important diagnostic dilemma...
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker
Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).
Very few studies have followed patients with renal cell carcinoma for long enough to characterize late relapses. Newly published research suggests that late-recurring tumours are more likely to be of low nuclear grade and show a better response...
Evidence from a Meta-Analysis of Observational Studies
|NeonCRM by Neon One|